Advancedapplied biology
HeLa Cells: Henrietta Lacks and the Ethics of Immortality
Learning objectives
- Narrate how HeLa cells were established and why they mattered scientifically.
- Explain the consent failure and its historical context.
- Describe the Lacks family's experience and the path to recognition.
- Analyze the case's impact on research ethics and tissue policy.
Background: The Cells That Would Not Die
In 1951, Henrietta Lacks, a 31-year-old Black mother of five, sought treatment at Johns Hopkins Hospital in Baltimore for cervical cancer. During her care, a sample of her tumor tissue was taken — as was routine at the time — and passed to researcher George Gey, who had spent decades trying to grow human cells in continuous culture. Lacks's cells did something no human cells had done before: they survived, divided, and kept dividing, doubling roughly every day. They became HeLa — the first immortal human cell line. Henrietta Lacks died of her cancer later that year, at 31, and was buried in an unmarked grave. She never knew that her cells lived on. For two decades, neither did her family. Meanwhile HeLa cells were shipped worldwide, becoming the workhorse of modern biomedical research: they were used to develop the polio vaccine, to study cancer and viruses, to map genes, and to test the effects of radiation and toxins. An entire biotechnology industry grew, in part, from those cells — while the Lacks family, learning of HeLa only in the 1970s, lived without health insurance and without any share of the benefits.
HeLa cells show that scientific progress and ethical failure can share the same source — and that justice in research means recognizing the people behind the materials.
What Happened: Immortal Cells, Invisible Family
The scientific value of HeLa is difficult to overstate. Before HeLa, human cells in culture died within days, making sustained experimentation impossible; after HeLa, researchers had a standardized, endlessly renewable human cell system. The cells' robustness — they grew vigorously, tolerated shipping, and adapted to countless conditions — made them the default model for cell biology. But the human story unfolded in parallel and in painful contrast. When researchers contacted the Lacks family in the 1970s seeking blood samples for genetic studies, the family learned for the first time that Henrietta's cells were alive in laboratories worldwide. They had not consented, had not been asked, and had received nothing — not information, not acknowledgment, not compensation — while companies profited. Journalist Rebecca Skloot's 2010 book, The Immortal Life of Henrietta Lacks, written with the family's cooperation, brought this story to millions and forced a public reckoning. In 2013, the NIH reached an agreement with the family giving them a voice in controlling access to HeLa genomic data. In 2023, the family reached a settlement with Thermo Fisher Scientific, one of the companies that had commercialized the cells.
The Biological Mechanism: Immortality and Its Costs
HeLa's immortality has a molecular explanation. The cells express active telomerase, the enzyme that rebuilds chromosome ends, escaping the Hayflick limit — the roughly 50 divisions after which normal human cells senesce. They also carry the genetic chaos of an aggressive cervical cancer, including human papillomavirus DNA integrated into the genome, which helped drive their relentless proliferation. This same robustness made HeLa a notorious contaminant: because the cells grow so aggressively, they invaded and overtook other cell cultures in laboratories worldwide, invalidating years of research before contamination was detected — a cautionary tale in cell culture technique. Ethically, the case turns on consent and justice. In 1951, taking tissue without consent was legal and routine; no framework of informed consent for research existed. The wrong, as later generations judged it, was not only the taking but everything after: the decades of silence, the profits without sharing, and the racial dimension — a Black woman's body fueling an industry in a segregated medical system. Modern regulations requiring informed consent for tissue research exist in large part because of cases like this one.
Outcome and Lessons: Consent, Justice, and Trust
The HeLa story's resolution is still being written, but its influence on research ethics is settled. It is now taught alongside Tuskegee as a foundational case: the reason modern science requires informed consent, institutional review, and attention to justice — who benefits and who bears the burdens of research. It prompted reexamination of tissue rights: do patients own their excised tissues, and what is owed when those tissues generate value? Policies on de-identification, broad consent for biobanks, and benefit-sharing all bear HeLa's imprint. For the Lacks family, recognition came slowly — a portrait at the Smithsonian, the NIH agreement, the 2023 settlement — but it came, driven by their persistence and by a public that learned Henrietta Lacks's name. The deepest lesson is about the relationship between science and the people it studies: cells are never just materials; they come from persons, with families, histories, and rights. Remembering that is not an obstacle to research — it is what makes research worthy of trust.
Exam Angle: Science and Justice Together
HeLa questions require both scientific accuracy and ethical sensitivity. For the biology, explain immortality through telomerase and the escape from the Hayflick limit, and note HeLa's role in the polio vaccine and as a contamination cautionary tale. For the ethics, state the facts plainly: cells taken in 1951 without knowledge or consent, family uninformed for decades, profits without sharing. Present the milestones of recognition — Skloot's 2010 book, the 2013 NIH agreement, the 2023 settlement — as the arc toward justice. If asked about current policy, connect the case to informed consent requirements and biobank governance. Write about Henrietta Lacks as a person, not a specimen: the respectful tone is part of the correct answer.
Henrietta Lacks was a mother of five whose cells changed medicine. Her family's decades-long fight for recognition is as much the story as the science.
Key points
- Henrietta Lacks, a Black woman treated for cervical cancer in 1951, was the source of HeLa cells.
- Her cells, taken without her knowledge or consent, became the first immortal human cell line.
- HeLa cells enabled the polio vaccine, cancer research, gene mapping, and countless discoveries.
- The Lacks family learned of the cells decades later and received no compensation for generations.
- The case reshaped debates on consent, tissue rights, and justice in research.
Common misconceptions
✓ Truth: The cells were taken during her cancer treatment without her knowledge or consent — standard practice at the time, but not donation, and the distinction matters.
✓ Truth: No law required consent for tissue research then. The ethical failure is judged by later standards — which is precisely why the case drove the creation of those standards.
✓ Truth: HeLa remains one of the most widely used cell lines in the world, still essential in active research areas decades after its establishment.
Frequently asked questions
What was the 2013 NIH agreement?
In 2013, the NIH reached an agreement with the Lacks family: researchers could access the HeLa genome data, but a family-inclusive committee would review applications. It was a landmark acknowledgment of the family's stake.
How did the public learn Henrietta Lacks's story?
Rebecca Skloot's 2010 book The Immortal Life of Henrietta Lacks brought the family's story to wide public attention and is largely responsible for the modern reckoning with the case.
Was there a legal settlement over HeLa cells?
In 2023 the Lacks family reached a settlement with Thermo Fisher Scientific, a company that had profited from HeLa cells. The family's broader campaign for recognition and compensation continues.